copy and paste this google map to your website or blog!
Press copy button and paste into your blog or website.
(Please switch to 'HTML' mode when posting into your blog. Examples: WordPress Example, Blogger Example)
Input Form:Deal with this potential dealer,buyer,seller,supplier,manufacturer,exporter,importer
(Any information to deal,buy, sell, quote for products or service)
Homepage | Pfizer Canada Pfizer Canada ULC is the Canadian operation of Pfizer Inc , one of the world's leading biopharmaceutical companies At Pfizer, we apply science and our global resources to bring therapies to people that help extend and improve their lives
Contact Us | Pfizer Canada To report an adverse event (or suspected side-effect) experienced with a Pfizer medication (prescription or a vaccine), please contact us by phone, at 1 866 723-7111, or by fax, at 1 855 242-5652 Reports can also be made directly to Health Canada through the Canada Vigilance Program at 1 866 234-2345
Pfizer Canada and BioNTech Receive Health Canada Approval of Omicron KP . . . Pfizer Canada ULC and BioNTech SE announced that Health Canada has authorized the KP 2 variant adapted COMIRNATY COVID-19 vaccine for ages 6 months and older The updated COMIRNATY vaccine targets the Omicron KP 2 variant, one of the most recently circulating SARS-CoV-2 lineages
Our Products | Pfizer Canada Our diversified health care portfolio includes some of the world’s best-known prescription medicines and vaccines If you encounter difficulties in viewing our product information please refer to the Health Canada Drug Product Database site
PADCEV ® (enfortumab vedotin) in combination with . . . - Pfizer Pfizer Canada ULC today announced that Health Canada has approved PADCEV® (enfortumab vedotin) an antibody-drug conjugate (ADC) in combination with pembrolizumab, a PD-1 inhibitor, for the treatment of adult patients with unresectable locally advanced or metastatic urothelial cancer (la mUC)
ABRYSVO: Pfizer Canada’s Newly Publicly Funded Vaccine a Step Towards . . . Pfizer Canada ULC announced that ABRYSVO™ has been selected as the publicly-funded vaccine for the prevention of Respiratory Syncytial Virus (RSV) in older adults in Canada for 2024-2025 ABRYSVO™ is approved by Health Canada for the prevention of lower respiratory tract disease caused by RSV in adults 60 years of age
COMIRNATY (COVID-19 mRNA vaccine) [Omicron KP. 2 variant] | Pfizer Canada Please contact Pfizer Canada Medical Information at 1 800 463-6001 with any comments or inquiries If you would like to report an adverse event related to Pfizer's COVID-19 vaccine, we encourage you to visit our designated safety web portal, where you can efficiently and seamlessly report your experience with the Pfizer Covid-19 vaccine
Health Canada Approves Pfizer’s Bivalent Respiratory Syncytial Virus . . . Kirkland, QC, January 4, 2023 - Pfizer Canada ULC announces the Health Canada approval of ABRYSVO TM, its bivalent Respiratory Syncytial Virus (RSV) vaccine The vaccine is indicated for the prevention of lower respiratory tract disease caused by RSV in individuals 60 years of age and older by active immunization, and the prevention of lower
ELREXFIO™ is authorized by Health Canada for adults with . . . - Pfizer In line with the NOC c authorization for ELREXFIO, Pfizer will continue its clinical development program investigating ELREXFIO’s use across the entire spectrum of myeloma progression, from newly diagnosed multiple myeloma to RRMM Supply of ELREXFIO is now available in Canada
Crohn’s and Colitis Canada and Pfizer Canada Introduce the 2024 . . . In partnership with Crohn’s and Colitis Canada, we are thrilled to announce our 2024 IBD research joint awards program, now in its fifth year, aimed at empowering Inflammatory Bowel Disease (IBD) research and driving diversity, equity, and inclusion in patient care